Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +49.35%
#3 Glidr Glidr +35.94%
#4 Cysic Cysic +24.17%
#5 Nockchain Nockchain +17.60%
#6 Nillion Nillion +15.06%
#7 FOLKS FOLKS +14.14%
#8 Tutorial Tutorial +13.17%
#9 Humanity Humanity +13.15%
#10 Velvet Velvet +13.00%
Coin of the day
EXOD EXOD
설정
언어
한국어
통화
USD
테마
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
주식 순위 #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
주가
$0.051239
마지막 동기화: 2025-11-24
시가총액
$1.38M
변동 (1일)
-4.48%
변동 (1년)
-54.57%
국가
NO
거래 BerGenBio ASA (BGBIO)

카테고리

Healthcare
BerGenBio ASA (BGBIO)의 주식 분할 이력
BerGenBio ASA 주식 (심볼: BGBIO)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 15, 2026에 발생했습니다.
Aug 15, 2026 이전에 매수한 BGBIO 주식 1주는 현재 0주의 BGBIO 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 0 -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0 -
BE